Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China - Trial NCT06078995
Access comprehensive clinical trial information for NCT06078995 through Pure Global AI's free database. This phase not specified trial is sponsored by Huashan Hospital and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 1200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Huashan Hospital
Timeline & Enrollment
N/A
Apr 02, 2023
May 01, 2024
Primary Outcome
Rate of patients with symptomatic intracranial hemorrhage within 36 hours
Summary
The objective of the study is to investigate the effectiveness and safety of rhTNK-tPA in
 acute ischemic stroke patients within 4.5 hours of symptom onset in a real-world clinical
 setting.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06078995
Non-Device Trial